Spear Pharmaceutical’s Generic to Efudex sold to Mayne Pharmaceuticals

• Mayne Pharma Group Limited (“Mayne Pharma”) (ASX: MYX) has acquired generic Efudex® (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc. (“Spear”) for up to US$30.0 million

• Product is immediately EPS accretive with an implied acquisition EBITDA multiple in the low single digits

• Mayne Pharma will fund the acquisition from cash and undrawn debt

Read the full article here: https://www.maynepharma.com/media/2107/mayne-pharma-acquires-generic-efudex-complementing-us-dermatology-portfolio.pdf